Extracellular vesicles demonstrate significant potential as diagnostic biomarkers and therapeutic agents across multiple diseases, though clinical translation requires standardized quality control and large-scale validation.
Extracellular vesicles represent a promising frontier for precision medicine as both diagnostic biomarkers and therapeutic agents, though significant translational challenges remain before widespread clinical implementation.
Extracellular vesicles (EVs) have emerged as pivotal mediators of intercellular communication and promising theranostic agents in medicine. These naturally-derived nanoparticles possess unique advantages including stable physicochemical properties, low immunogenicity, and inherent biocompatibility. In recent years, increasing attention has been directed toward clinical investigations. Driven by these clinical studies, several EV-based diagnostic and therapeutic products have emerged. In this review, we aimed to highlight and discuss the completed and emerging clinical investigations of EV-based strategies, critically elucidate persistent technical and translational hurdles impeding clinical implementation, and propose strategic directions to accelerate realization of the transformative potential inherent in EV-mediated precision medicine.
Zou et al. (Mon,) conducted a review in Various diseases (Cancer, Respiratory, Neurological, Autoimmune). Extracellular vesicles (EVs) was evaluated. Extracellular vesicles demonstrate significant potential as diagnostic biomarkers and therapeutic agents across multiple diseases, though clinical translation requires standardized quality control and large-scale validation.